Discovery of APD334: Design of a clinical stage functional antagonist of the sphingosine-1-phosphate-1 receptor

ACS Medicinal Chemistry Letters

Volumn 5, Issue 12, 2014, Pages 1313-1317

  Buzard, Daniel J ^a   Kim, Sun Hee ^a   Lopez, Luis ^a   Kawasaki, Andrew ^a   Zhu, Xiuwen ^a   Moody, Jeanne ^a   Thoresen, Lars ^a   Calderon, Imelda ^a   Ullman, Brett ^a   Han, Sangdon ^a   Lehmann, Juerg ^a   Gharbaoui, Tawfik ^a   Sengupta, Dipanjan ^a   Calvano, Lorene ^a   Montalban, Antonio Garrido ^a   Ma, You An ^a   Sage, Carleton ^a   Gao, Yinghong ^a   Semple, Graeme ^a   Edwards, Jeff ^a   Barden, Jeremy ^a   Morgan, Michael ^a   Chen, Weichao ^a   Usmani, Khawja ^a   Chen, Chuan ^a   Sadeque, Abu ^a   Christopher, Ronald J ^a   Thatte, Jayant ^a   Fu, Lixia ^a   Solomon, Michelle ^a   Mills, David ^a   Whelan, Kevin ^a   Al Shamma, Hussien ^a   Gatlin, Joel ^a   Le, Minh ^a   Gaidarov, Ibragim ^a   Anthony, Todd ^a   Unett, David J ^a   Blackburn, Anthony ^a   Rueter, Jaimie ^a   Stirn, Scott ^a   Behan, Dominic P ^a   Jones, Robert M ^a   more..

^a ARENA PHARMACEUTICALS   (United States)

Author keywords

APD334; fingolimod; FTY720; gilenya; S1P1< inf>; Sphingosine 1 phosphate

Indexed keywords

2 [7 [[4 CYCLOPENTYL 3 (TRIFLUOROMETHYL)BENZYL]OXY] 1,2,3,4 TETRAHYDRO CYCLOPENTA[B]INDOL 3 YL]ACETIC ACID; FINGOLIMOD; IMMUNOSUPPRESSIVE AGENT; PROTEIN INHIBITOR; SPHINGOSINE 1 PHOSPHATE RECEPTOR; SPHINGOSINE 1 PHOSPHATE RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTHRITIS; ARTICLE; CONTROLLED STUDY; DOG; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FEMALE; HAPLORHINI; HUMAN; HUMAN CELL; LIVER MICROSOME; LYMPHOCYTE; LYMPHOCYTE COUNT; MAXIMUM PLASMA CONCENTRATION; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION;

RATTUS;

EID: 84918563892     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml500389m     Document Type: Article

References (24)

1. O'Sullivan, C.; Dev, K. K. The Structure and Function of the S1P1 Receptor Trends Pharmacol. Sci. 2013, 34, 401-412
2. Brinkmann, V. Sphingosine 1-Phosphate Receptors in Health and Disease: Mechanistic Insights from Gene Deletion Studies and Reverse Pharmacology Pharmacol. Ther. 2007, 115, 84-105
3. Chun, J.; Brinkman, V. A Mechanistically Novel, First Oral Therapy for Multiple Sclerosis: The Development of Fingolimod (FTY720, Gilenya) Discovery Med. 2011, 12, 213-228
4. Hale, J. J.; Yan, L.; Neway, W. E.; Hajdu, R.; Bergstrom, J. D.; Milligan, J. A.; Shei, G.-J.; Chrebet, G. L.; Thornton, R. A.; Card, D.; Rosenbach, M.; Rosen, H.; Mandala, S. Synthesis, Stereochemical Determination and Biochemical Characterization of the Enantiomeric Phosphate Esters of the Novel Immunosuppressive Agent FTY720 Bioorg. Med. Chem. 2004, 12, 4803-4807
5. Oo, M. L.; Thangada, S.; Wu, M.-T.; Liu, C. H.; Macdonald, T. L.; Lynch, K. R.; Lin, C.-Y.; Hla, T. Immunosuppressive and Anti-angiogenic Sphingosine 1-Phosphate Receptor-1 Agonists Induce Ubiquitinylation and Proteasomal Degradation of the Receptor J. Biol. Chem. 2007, 282, 9082-9289
6. Matloubian, M.; Lo, C. G.; Cinamon, G.; Lesneski, M. J.; Xu, Y.; Brinkmann, V.; Allende, M. L.; Proia, R. L.; Cyster, J. G. Lymphocyte Egress from Thymus and Peripheral Lymphoic Organs is Dependent on S1P Receptor 1 Nature 2004, 427, 355-360
7. Chun, J.; Hartung, H.-P. Mechanism of Action of Oral Fingolimod (FTY720) in Multiple Sclerosis Clin. Neuropharmacol. 2010, 33, 91-101
8. Choi, J. W.; Gardell, S. E.; Herrr, D. R.; Rivera, R.; Lee, C.-W.; Noguchi, K.; Teo, S. T.; Yung, Y. C.; Lu, M.; Kennedy, G.; Chun, J. FTY720 (Fingolimod) Efficacy in an Animal Model of Multiple Sclerosis Requires Astrocyte Sphingosine 1-Phosphate Receptor 1 (S1P1) Modulation Proc. Natl. Acad. Sci. U.S.A. 2011, 108, 751-756
9. Dyckman, A. J. Recent Advancements in Discovery and Development of Sphingosine-1-Phosphate-1 Receptor Agonists Annu. Rep. Med. Chem. 2012, 47, 195-207
10. Van Doorn, R.; Lopes Pinheiro, M. A.; Kooij, G.; Lakeman, K.; von het hof, B.; van der Pol, S.; Geerts, D.; van Horssen, J.; van der Valk, P.; van der Kam, E.; Ronken, E.; Reijerkerk, A.; de Vries, H. E. Sphingosine 1-phosphate Receptor 5 Mediates the Immune Quiescence of the Human Brain Endothelial Barrier J. Neuroinflamm. 2012, 10, 1186/1742-2094-9-133
11. Schulze, T.; Golfier, S.; Tabeling, C.; Rabel, K.; Graler, M.; Witzenrath, M.; Lipp, M. Sphingosine-1-phosphate Receptor 4 (S1P4) Deficiency Profoundly Affects Dendritic Cell Function and TH17-cell Differentiation in a Murine Model FASEB J. 2011, 25, 4024-4036
12. Jadidi-Niaragh, F.; Mirshafiey, A. The Th17 Cell, the New Player of Neuroinflammatory Process in Multiple Sclerosis Scand. J. Immunol. 2011, 74, 1-13
13. Koyrakh, L.; Roman, M. I.; Brinkmann, V.; Wickman, K. The Heart Rate Decrease Caused by Acute FTY720 Administration is Mediated by the G Protein-Gated Potassium Channel I IKACh Am. J. Transplant. 2005, 5, 529-536
14. Gergely, P.; Nuesslein-Hildesheim, B.; Guerni, D.; Brinkmann, V.; Traebert, M.; Bruns, C.; Pan, S.; Gray, N. S.; Hinterding, K.; Cooke, N. G.; Groenewegen, A.; Vitaliti, A.; Sing, T.; Luttringer, O.; Yang, J.; Gardin, A.; Wang, N.; Crumb, W. J., Jr.; Saltzman, M.; Rosenberg, M.; Wallstrom, E. The Selective Sphingosine 1-Phosphate Receptor Modulator BAF312 Redirects Lymphocyte Distribution and Has Species-Specific Effects on Heart Rate Br. J. Pharmacol. 2012, 167, 1035-1047
15. Katrin, S.; Menyhart, K.; Killer, N.; Renault, B.; Bauer, Y.; Studer, R.; Steiner, B.; Bolli, M. H.; Nayler, O.; Gatfield, J. Sphinosine 1-Phosphate (S1P) Receptor Agonists Mediate Pro-fibrotic Responses in Normal Human Lung Fibroblasts via S1P2 and S1P3 Receptors and Smad-independent Signaling J. Biol. Chem. 2013, 288, 14839-14851
16. Takuwa, N.; Okamoto, Y.; Yoshioka, K.; Takuwa, Y. Sphingosine-1-phosphate Signaling and Cardiac Fibrosis Inflamm. Regen. 2013, 33, 96-108
17. Kovarik, J. M.; Schmouder, R.; Barilla, R.; Riviere, G.-J.; Wang, Y.; Hunt, T. Multiple-Dose FTY720: Tolerability, Pharmacokinetics, and Lymphocyte Responses in Healthy Subjects J. Clin. Pharmacol. 2013, 44, 532-537
18. Pelletier, D.; Hafler, D. A. Fingolimod for Multiple Sclerosis N. Engl. J. Med. 2012, 366, 339-347
19. Demont, E.; Arpino, S.; Bit, R.; Campbell, C.; Deeks, N.; Desai, S.; Dowell, S.; Gaskin, P.; Gray, J.; Harrison, L.; Haynes, A.; Heightman, T.; Holmes, D.; Humphreys, P.; Kumar, U.; Morse, M.; Osborne, G.; Panshal, T.; Philpott, K.; Taylor, S.; Watson, R.; Willis, R.; Witherington, J. Discovery of a Brain-penetrant S1P3-sparing Direct Agonist of the S1P1 and S1P5 Receptors Efficacious at Low Oral Dose J. Med. Chem. 2011, 54, 6724
20. Buzard, D.; Han, S.; Thorsen, L.; Moody, J.; Lopez, L.; Kawasaki, A.; Schrader, T.; Sage, C.; Gao, Y.; Edwards, J.; Barden, J.; Thatte, J.; Fu, L.; Soloman, M.; Liu, L.; Al-Shamma, H.; Gatlin, J.; Le, M.; Xing, C.; Espinola, S.; Jones, R. M. Discovery and Characterization of Potent and Selective 4-Oxo-4-(5-(5-phenyl-1,2,4-oxadiazol-3-yl)indolin-1-yl)butanoic acids as S1P1 Agonists Bioorg. Med. Chem. Lett. 2011, 21, 6013-6018
21. Buzard, D.; Han, S.; Lopez, L.; Kawasaki, A.; Moody, J.; Thoresen, L.; Ullman, B.; Lehmann, J.; Calderon, I.; Zhu, X.; Gharbaoui, T.; Sengupta, D.; Krishnan, A.; Gao, Y.; Edwards, J.; Barden, J.; Morgan, M.; Usmani, K.; Chen, C.; Sadeque, A.; Thatte, J.; Solomon, M.; Fu, L.; Whelan, K.; Liu, L.; Al-Shamma, H.; Gatlin, J.; Le, M.; Xing, C.; Espinola, S.; Jones, R. M. Fused Tricyclic Indoles as S1P1 Agonists with Robust Efficacy in Animal Models of Autoimmune Disease Bioorg. Med. Chem. Lett. 2012, 22, 4404-4409
22. Macrae, C. F.; Bruno, I. J.; Chisholm, J. A.; Edgington, P. R.; McCabe, P.; Pidcock, E.; Rodriguez-Monge, L.; Taylor, R.; van de Streek, J.; Wood, P. A. Mercury CSD 2.0: New Features for the Visualization and Investigation of Crystal Structures J. Appl. Crystallogr. 2008, 41, 466-470
23. Pan, S.; Gray, N. S.; Gao, W.; Mi, Y.; Fan, Y.; Wang, X.; Tuntland, T.; Che, J.; Lefebvre, S.; Chen, Y.; Chu, A.; Hinterding, K.; Gardin, A.; End, P.; Heining, P.; Bruns, C.; Cooke, N. G.; Nuesslein-Hildesheim, B. Discovery of BAF312 (Siponimod), a P0tent and Selective S1P Receptor Modulator ACS Med. Chem. Lett. 2013, 4, 333-337
24. Constantinescu, C. S.; Farooqi, N.; O'Brien, K.; Gran, B. Experimental Autoimmune Encephalomyelitis (EAE) as a Model for Multiple Sclerosis (MS) Br. J. Pharmacol. 2011, 164, 1079-1106